Literature DB >> 7873642

Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds.

R J Kreitman1, J K Batra, S Seetharam, V K Chaudhary, D J FitzGerald, I Pastan.   

Abstract

Anti-Tac(Fv)-PE40 is a recombinant single-chain immunotoxin in which the variable heavy and light domains of the anti-IL2 receptor antibody, anti-Tac, are connected to each other by a peptide linker and then fused to PE40, a truncated form of Pseudomonas exotoxin (PE). This fusion protein has four disulfide bonds: one in each of the two variables domains, one in domain II (Cys 265-287), and one in domain Ib (Cys 372-379) of PE. To study the importance of the disulfide bonds of the toxin to the activity of single-chain immunotoxins, we constructed mutants in which either the cysteines in the toxin were changed to alanines or the amino acids 365-380 of PE were deleted. We began this study with anti-Tac(Fv)-PE40 and a more active variant, anti-Tac(Fv)-PE40KDEL, in which the carbonyl terminus is changed from REDLK to KDEL. From these proteins we made anti-Tac(Fv)-PE40(4)A and anti-Tac(Fv)-PE40KDEL4A, respectively, by converting cysteins at amino acids 265, 287, 372, and 379 of PE to alanines. This change resulted in a 20-100-fold loss of activity toward human target cells, but no significant change in binding affinity to p55. To determine the importance of the second toxin disulfide bond, we removed amino acids 365-380 from anti-Tac(Fv)-PE40, anti-Tac(Fv)-PE40KDEL, and anti-Tac(Fv)-PE40KDEL4A, resulting in anti-Tac(Fv)-PE38, anti-Tac(Fv)-PE38KDEL, and anti-Tac(Fv)-PE38KDEL2A, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7873642     DOI: 10.1021/bc00020a002

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   6.069


  19 in total

Review 1.  Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.

Authors:  Robert J Kreitman; Ira Pastan
Journal:  Clin Cancer Res       Date:  2011-10-15       Impact factor: 12.531

2.  Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.

Authors:  Rajat Singh; Yujian Zhang; Ira Pastan; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2011-11-08       Impact factor: 12.531

Review 3.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

4.  Renal excretion of recombinant immunotoxins containing pseudomonas exotoxin.

Authors:  Roberta Traini; Robert J Kreitman
Journal:  Bioconjug Chem       Date:  2011-03-16       Impact factor: 4.774

5.  Novel cholix toxin variants, ADP-ribosylating toxins in Vibrio cholerae non-O1/non-O139 strains, and their pathogenicity.

Authors:  Sharda Prasad Awasthi; Masahiro Asakura; Nityananda Chowdhury; Sucharit Basu Neogi; Atsushi Hinenoya; Hossain M Golbar; Jyoji Yamate; Eiji Arakawa; Toshiji Tada; T Ramamurthy; Shinji Yamasaki
Journal:  Infect Immun       Date:  2012-12-10       Impact factor: 3.441

6.  Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.

Authors:  Daniel J Powell; Aloisio Felipe-Silva; Maria J Merino; Mojgan Ahmadzadeh; Tamika Allen; Catherine Levy; Donald E White; Sharon Mavroukakis; Robert J Kreitman; Steven A Rosenberg; Ira Pastan
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

Review 7.  Immunoconjugates in the management of hairy cell leukemia.

Authors:  Robert J Kreitman; Ira Pastan
Journal:  Best Pract Res Clin Haematol       Date:  2015-10-09       Impact factor: 3.020

8.  Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.

Authors:  Peter Attia; Daniel J Powell; Ajay V Maker; Robert J Kreitman; Ira Pastan; Steven A Rosenberg
Journal:  J Immunother       Date:  2006 Mar-Apr       Impact factor: 4.456

Review 9.  Approach to the patient after relapse of hairy cell leukemia.

Authors:  Robert J Kreitman; David J P Fitzgerald; Ira Pastan
Journal:  Leuk Lymphoma       Date:  2009-10

Review 10.  Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.

Authors:  Robert J Kreitman
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.